☰

Global

COMUNICADO: Janssen envía la aplicación de autorización de marketing de daratumumab (y 3)


    1) American Society of Clinical Oncology. Multiple myeloma: overview. Disponible a

    través de: http://www.cancer.net/cancer-types/multiple-myeloma/overview. Ultimo acceso

    18 de mayo de 2015.

    2) Kumar, SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple

    myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international

    myeloma working group study. Leukemia. 2012;26(1):149-57.

    3) Danylesko I, Beider K, Shimoni A, Nagler A. Monoclonal antibody-based immunotherapy

    for multiple myeloma. Immunotherapy. 2012;4:919-38.

    4) Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action

    in multiple myeloma in 2013: a report from the International Myeloma Working Group

    (IMWG). Leukemia. 2014;28:525-542.

    5) Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306

    cases of multiple myeloma. Am J Clin Pathol. 2004;121:482-8.

    6) Fedele G, di Girolamo M, Recine U, et al. CD38 ligation in peripheral blood

    mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and

    impaired secretion of IFNgamma cytokines and proliferation. Mediat Inflamm.

    2013;2013:564687.

    7) de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human

    CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological

    tumors. J Immunol. 2011;186:1840-8.

    8) Lonial S, Weiss BM, Usmani SZ, et al. Phase 2 Study of daratumumab Monotherapy in

    Patients with mayor o igual que3 Lines of Prior Therapy or Double Refractory Multiple

    Myeloma (MM). J Clin Oncol. 2015;33(Suppl.):abstract LBA 8512.

    9) Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with Daratumumab Monotherapy

    in Multiple Myeloma. N Engl J Med. 2015;Aug:1-13.

    10) European Medicines Agency. Public Summary of Orphan Drug Designations - EU/3/13/1153.

    Disponible a través de:

    http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2013/08/huma

    n_orphan_001232.jsp&mid=WC0b01ac058001d12b Ultimo acceso 12 de mayo de 2015.

    11) GLOBOCAN 2012. Multiple myeloma. Disponible a través

    de: http://globocan.iarc.fr/old/burden.asp?selection_pop=62968&Textp=Europe&selection

    _cancer=17270&Text-c=Multiple+myeloma&pYear=13&type=0&window=1&submit=%C2%A0Execute. 

    Ultimo acceso 13 de mayo de 2014.

    12) American Cancer Society. Multiple myeloma: detailed guide. Disponible a través de:

    http://www.cancer.org/acs/groups/cid/documents/webcontent/003121-pdf.pdf Ultimo acceso

    18 de mayo de 2015.

    13) Cancer Research UK. Myeloma Survival Statistics. Disponible a través de:

    http://www.cancerresearchuk.org/cancer-info/cancerstats/types/myeloma/survival/multipl

    e-myeloma-survival-statistics Ultimo acceso 18 de mayo de 2015.

    14) Costa LJ, Gonsalves WI, Kumar SK. Early mortality in multiple myeloma. Leukemia.

    2015;29:1616-8.

     

    Consultas de medios: 

    Natalie Buhl 

    Móvil: +353(0)85-744-6696 

    E-mail: nbuhl@its.jnj.com 

    EmptyBreak:MARKER 

    Relaciones con los inversores: 

    Lesley Fishman 

    Teléfono: +1-732-524-3922 

    EmptyBreak:MARKER 

    Louise Mehrotra 

    Teléfono: +1-732-524-6491 

     

     

    Septiembre de 2015 

    PHEM/DAT/0815/0002 

     

    .

    .

    Photo:

    http://photos.prnewswire.com/prnh/20140324/NY88746LOGO